Is Coherus Oncology, Inc. (NASDAQ:CHRS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Coherus Oncology, Inc. at current levels.
A pure-play oncology micro-cap trading like it's going to zero, with two shots on goal the market has written off entirely.
Where CHRS is headed
Coherus today is a $228M market cap company sitting on a commercial oncology asset (LOQTORZI) growing into its first full year as the only FDA-approved PD-1 in nasopharyngeal carcinoma, plus a biosimilar cash cow (UDENYCA) that the market has decided is already dead. By late 2027, the company most people aren't watching is one where LOQTORZI is doing $150-200M in annual sales as community oncologists move it into earlier lines, casdozokitug has produced a readout in hepatocellular carcinoma that either validates the IL-27 mechanism or kills it cleanly, and CHS-114 has given the first real human data on whether selectively depleting tumor-infiltrating Tregs without touching peripheral Tregs is the trick that makes anti-CCR8 work.
Read the full Compass Direction on CHRS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $1.48).
See the full CHRS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Coherus Oncology, Inc. (NASDAQ:CHRS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Coherus Oncology, Inc. at current levels. A pure-play oncology micro-cap trading like it's going to zero, with two shots on goal the market has written off entirely.
What is CHRS's Compass Score?
Coherus Oncology, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for CHRS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CHRS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.